Combination of lentivector immunization and low-dose chemotherapy or PD-1/PD-L1 blocking primes self-reactive T cells and induces anti-tumor immunity

European Journal of Immunology

Volumn 41, Issue 8, 2011, Pages 2217-2228

  Sierro, Sophie R ^a   Donda, Alena ^b   Perret, Rachel ^a   Guillaume, Philippe ^a   Yagita, Hideo ^c   Levy, Frédéric ^d   Romero, Pedro ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d DEBIOPHARM SA   (Switzerland)

Author keywords

Combination therapies; Immunotherapy; Lentiviral vector; Tumor

Indexed keywords

ANTIBODY; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYTOKINE; LENTIVIRUS VECTOR; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CD8+ T LYMPHOCYTE; CELL SPECIFICITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; FEMALE; GENE EXPRESSION; IMMUNOREACTIVITY; IMMUNOSTIMULATION; LENTIVIRINAE; LOW DRUG DOSE; LUNG METASTASIS; LYMPHOCYTE COUNT; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR IMMUNITY; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT;

ANIMALS; ANTIBODIES, BLOCKING; ANTIGENS, CD80; ANTIGENS, DIFFERENTIATION; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITOPES; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; IMMUNIZATION; INTERFERON-GAMMA; INTRAMOLECULAR OXIDOREDUCTASES; LENTIVIRUS; LYMPHOCYTE COUNT; MELANOMA, EXPERIMENTAL; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; PEPTIDES; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79960732805     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201041235     Document Type: Article

References (57)

1. Curran, M. A., Montalvo, W., Yagita, H. and Allison, J. P., PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc. Natl. Acad. Sci. USA 2010. 107: 4275-4280.
2. Zitvogel, L., Tesniere, A., Apetoh, L., Ghiringhelli, F. and Kroemer, G., Immunological aspects of anticancer chemotherapy. Bull. Acad. Natl. Med. 2008. 192: 1469-1487; discussion 1487-1469.
3. Peggs, K. S., Quezada, S. A. and Allison, J. P., Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy. Immunol. Rev. 2008. 224: 141-165.
4. + T cell immunity. Nat. Med. 2010. 16: 339-345.
5. Chapatte, L., Colombetti, S., Cerottini, J. C. and Levy, F., Efficient induction of tumor antigen-specific CD8 memory T cells by recombinant lentivectors. Cancer Res. 2006. 66: 1155-1160.
6. Cervantes-Barragan, L., Zuest, R., Maier, R., Sierro, S., Janda, J., Levy, L., Speiser, D. et al., Dendritic cell-specific antigen delivery by coronavirus vaccine vectors induces long-lasting protective antiviral and antitumor immunity. mBio 2010. 1: e00171-10.
7. + T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J. Clin. Invest. 2005. 115: 739-746.
8. Karbach, J., Gnjatic, S., Bender, A., Neumann, A., Weidmann, E., Yuan, J., Ferrara, C. A. et al., Tumor-reactive CD8+T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and montanide ISA-51: association with survival. Int. J. Cancer 2010. 126: 909-918.
9. + T cells in melanoma patients. J. Immunother. 2008. 31: 781-791.
10. + T cells in the circulation but not in the tumor site. J. Immunol. 2006. 177: 1670-1678.
11. Wherry, E. J., Blattman, J. N., Murali-Krishna, K., van der Most, R. and Ahmed, R., Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J. Virol. 2003. 77: 4911-4927.
12. +T cell expansion in melanoma patients. J. Immunol. 2009. 182: 5240-5249.
13. McWilliams, J., McGurran, S., Dow, S., Slansky, J. and Kedl, R., A modified tyrosinase-related protein 2 epitope generates high-affinity tumor-specific T cells but does not mediate therapeutic efficacy in an intradermal tumor model. J. Immunol. 2006. 177: 155-161.
14. Schreurs, M. W., Eggert, A. A., de Boer, A. J., Vissers, J. L., van Hall, T., Offringa, R., Figdor, C. G. and Adema, G. J., Dendritic cells break tolerance and induce protective immunity against a melanocyte differentiation antigen in an autologous melanoma model. Cancer Res. 2000. 60: 6995-7001.
15. Bronte, V., Apolloni, E., Ronca, R., Zamboni, P., Overwijk, W. W., Surman, D. R., Restifo, N. P. and Zanovello, P., Genetic vaccination with "self" tyrosinase-related protein 2 causes melanoma eradication but not vitiligo. Cancer Res. 2000. 60: 253-258.
16. Tuting, T., Steitz, J., Bruck, J., Gambotto, A., Steinbrink, K., DeLeo, A. B., Robbins, P. et al., Dendritic cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti-melanoma immunity. J. Gene Med. 1999. 1: 400-406.
17. Steitz, J., Bruck, J., Gambotto, A., Knop, J. and Tuting, T., Genetic immunization with a melanocytic self-antigen linked to foreign helper sequences breaks tolerance and induces autoimmunity and tumor immunity. Gene Ther. 2002. 9: 208-213.
18. Liu, Y., Peng, Y., Mi, M., Guevara-Patino, J., Munn, D. H., Fu, N. and He, Y., Lentivector immunization stimulates potent CD8T cell responses against melanoma self-antigen tyrosinase-related protein 1 and generates antitumor immunity in mice. J. Immunol. 2009. 182: 5960-5969.
19. Guevara-Patino, J. A., Engelhorn, M. E., Turk, M. J., Liu, C., Duan, F., Rizzuto, G., Cohen, A. D. et al., Optimization of a self antigen for presentation of multiple epitopes in cancer immunity. J. Clin. Invest. 2006. 116: 1382-1390.
20. Zhou, Q., Xiao, H., Liu, Y., Peng, Y., Hong, Y., Yagita, H., Chandler, P. et al., Blockade of programmed death-1 pathway rescues the effector function of tumor-infiltrating T cells and enhances the antitumor efficacy of lentivector immunization. J. Immunol. 2010. 185: 5082-5092.
21. Garcia Casado, J., Janda, J., Wei, J., Chapatte, L., Colombetti, S., Alves, P., Ritter, G. et al., Lentivector immunization induces tumor antigen-specific B and T cell responses in vivo. Eur. J. Immunol. 2008. 38: 1867-1876.
22. + T cells. Eur. J. Immunol. 2009. 39: 241-253.
23. +T-cell responses after immunization with recombinant lentivector. Blood 2009. 113: 6629-6637.
24. + T cell responses to antigen in lymph nodes and tissues. J. Immunol. 2007. 179: 5064-5070.
25. + T cell survival in HIV infection. J. Exp. Med. 2006. 203: 2281-2292.
26. Machiels, J. P., Reilly, R. T., Emens, L. A., Ercolini, A. M., Lei, R. Y., Weintraub, D., Okoye, F. I. and Jaffee, E. M., Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res. 2001. 61: 3689-3697.
27. Wada, S., Yoshimura, K., Hipkiss, E. L., Harris, T. J., Yen, H. R., Goldberg, M. V., Grosso, J. F. et al., Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model. Cancer Res. 2009. 69: 4309-4318.
28. + T cell precursor frequency determines the quality of the antitumor immune response. J. Exp. Med. 2009. 206: 849-866.
29. Ercolini, A. M., Ladle, B. H., Manning, E. A., Pfannenstiel, L. W., Armstrong, T. D., Machiels, J. P., Bieler, J. G. et al., Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J. Exp. Med. 2005. 201: 1591-1602.
30. Mueller, S. N., Vanguri, V. K., Ha, S. J., West, E. E., Keir, M. E., Glickman, J. N., Sharpe, A. H. and Ahmed, R., PD-L1 has distinct functions in hematopoietic and nonhematopoietic cells in regulating T cell responses during chronic infection in mice. J. Clin. Invest. 2010. 120: 2508-2515.
31. Singh, V., Ji, Q., Feigenbaum, L., Leighty, R. M. and Hurwitz, A. A., Melanoma progression despite infiltration by in vivo-primed TRP-2-specific T cells. J. Immunother. 2009. 32: 129-139.
32. Anderson, M. J., Shafer-Weaver, K., Greenberg, N. M. and Hurwitz, A. A., Tolerization of tumor-specific T cells despite efficient initial priming in a primary murine model of prostate cancer. J. Immunol. 2007. 178: 1268-1276.
33. Breckpot, K., Escors, D., Arce, F., Lopes, L., Karwacz, K., Van Lint, S., Keyaerts, M. and Collins, M., HIV-1 lentiviral vector immunogenicity is mediated by toll-like receptor 3 (TLR3) and TLR7. J. Virol. 2010. 84: 5627-5636.
34. Pichlmair, A., Diebold, S. S., Gschmeissner, S., Takeuchi, Y., Ikeda, Y., Collins, M. K. and Reis e Sousa, C., Tubulovesicular structures within vesicular stomatitis virus G protein-pseudotyped lentiviral vector preparations carry DNA and stimulate antiviral responses via toll-like receptor 9. J. Virol. 2007. 81: 539-547.
35. Fife, B. T., Pauken, K. E., Eagar, T. N., Obu, T., Wu, J., Tang, Q., Azuma, M. et al., Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat. Immunol. 2009. 10: 1185-1192.
36. + T cells in HIV infection. J. Immunol. 2009. 183: 1120-1132.
37. Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C. et al., Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 2002. 8: 793-800.
38. Hino, R., Kabashima, K., Kato, Y., Yagi, H., Nakamura, M., Honjo, T., Okazaki, T. and Tokura, Y., Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer 2010. 116: 1757-1766.
39. Blank, C., Brown, I., Peterson, A. C., Spiotto, M., Iwai, Y., Honjo, T. and Gajewski, T. F., PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+T cells. Cancer Res. 2004. 64: 1140-1145.
40. + T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat. Immunol. 2009. 10: 29-37.
41. + T cell dysfunction in melanoma patients. J. Exp. Med. 2010. 207: 2175-2186.
42. Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K. and Anderson, A. C., Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J. Exp. Med. 2010. 207: 2187-2194.
43. + T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc. Natl. Acad. Sci. USA 2010. 107: 7875-7880.
44. Brode, S. and Cooke, A., Immune-potentiating effects of the chemotherapeutic drug cyclophosphamide. Crit. Rev. Immunol. 2008. 28: 109-126.
45. + regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur. J. Immunol. 2004. 34: 336-344.
46. +T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005. 105: 2862-2868.
47. + regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular ATP levels. Cancer Res. 2010. 70: 4850-4858.
48. Salem, M. L., Al-Khami, A. A., El-Naggar, S. A., Diaz-Montero, C. M., Chen, Y. and Cole, D. J., Cyclophosphamide induces dynamic alterations in the host microenvironments resulting in a Flt3 ligand-dependent expansion of dendritic cells. J. Immunol. 2010. 184: 1737-1747.
49. Nakahara, T., Uchi, H., Lesokhin, A. M., Avogadri, F., Rizzuto, G. A., Hirschhorn-Cymerman, D., Panageas, K. S. et al., Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs. Blood 2010. 115: 4384-4392.
50. Escors, D., Lopes, L., Lin, R., Hiscott, J., Akira, S., Davis, R. J. and Collins, M. K., Targeting dendritic cell signaling to regulate the response to immunization. Blood 2008. 111: 3050-3061.
51. Tripathi, D. N. and Jena, G. B., Astaxanthin intervention ameliorates cyclophosphamide-induced oxidative stress, DNA damage and early hepatocarcinogenesis in rat: role of Nrf2, p53, p38 and phase-II enzymes. Mutat. Res. 2010. 696: 69-80.
52. Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K. et al., Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat. Med. 2009. 15: 1170-1178.
53. van der Most, R. G., Currie, A. J., Cleaver, A. L., Salmons, J., Nowak, A. K., Mahendran, S., Larma, I. et al., Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8T cell-mediated immune attack resulting in suppression of tumor growth. PLoS One 2009. 4: e6982.
54. Park, J. J., Omiya, R., Matsumura, Y., Sakoda, Y., Kuramasu, A., Augustine, M. M., Yao, S. et al., B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance. Blood 2010. 116: 1291-1298.
55. *0201 in melanoma cells. J. Immunol. 2004. 173: 6033-6040.
56. Esslinger, C., Chapatte, L., Finke, D., Miconnet, I., Guillaume, P., Levy, F. and MacDonald, H. R., In vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8(+) T cell responses. J. Clin. Invest. 2003. 111: 1673-1681.
57. Barber, D., Wherry, E. and Ahmed, R., Cutting edge: rapid in vivo killing by memory CD8T cells. J. Immunol. 2003. 171: 27-31.